发明名称 Stabilised tumour-antigen mRNA with increased G/C-content
摘要 Pharmaceutical composition (A) contains at least one modified mRNA (I) encoding a biologically active or antigenic (poly)peptide (II), plus a carrier and/or vehicle. Pharmaceutical composition (A) contains at least one modified mRNA (I) encoding a biologically active or antigenic (poly)peptide (II), plus a carrier and/or vehicle. (I) has, in the (II)-coding region: (i) a G/C content higher than that for the wild-type RNA; and/or (ii) at least one codon in the wild-type sequence, for which the tRNA is rare, is replaced by a codon, representing the same amino acid, for which the tRNA is common, but the amino acid sequence encoded by the modified mRNA is the same as that encoded by the wild type. ACTIVITY : Cytostatic; Virucide; Antibacterial; Protozoacide; Nootropic; Neuroprotective; Antiparkinsonian; Immunostimulant. No details of tests for any of these activities are given. MECHANISM OF ACTION : Gene Therapy; Vaccine. No biological data given.
申请公布号 EP1604688(B1) 申请公布日期 2010.02.03
申请号 EP20050004938 申请日期 2002.06.05
申请人 CUREVAC GMBH 发明人 VON DER MUELBE, FLORIAN;PASCOLO, STEVE;HOERR, INGMAR
分类号 A61K48/00;A61K38/00;A61K38/19;A61K39/00;A61K39/145;A61P31/16;A61P35/04;C07K14/11;C12N15/67;G06F19/18;G06F19/22 主分类号 A61K48/00
代理机构 代理人
主权项
地址